Ratings for Edwards Lifesciences EW were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $91.56, a high estimate of $103.00, and a low estimate of $77.00. Observing a 10.15% increase, the current average has risen from the previous average price target of $83.12.
Investigating Analyst Ratings: An Elaborate Study
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Wood | Morgan Stanley | Raises | Overweight | $103.00 | $95.00 |
| Suraj Kalia | Oppenheimer | Raises | Outperform | $100.00 | $93.00 |
| Rick Wise | Stifel | Raises | Hold | $83.00 | $70.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $95.00 | $80.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $95.00 | $82.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $95.00 | $85.00 |
| Larry Biegelsen | Wells Fargo | Announces | Overweight | $94.00 | - |
| Shagun Singh | RBC Capital | Raises | Outperform | $82.00 | $80.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $77.00 | $80.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edwards Lifesciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Edwards Lifesciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US
Edwards Lifesciences: A Financial Overview
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Edwards Lifesciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 13.78%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 24.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Edwards Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Edwards Lifesciences's ROA excels beyond industry benchmarks, reaching 3.95%. This signifies efficient management of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
